POSC138 The Burden Due to Moderate-to-Severe Paediatric Atopic Dermatitis Treated with Systemic Immunosuppressants on the Healthcare System in England

Abstract

Children and adolescents with moderate-to-severe atopic dermatitis (AD) which cannot be managed despite optimal use of topical therapies often require intervention with systemic immunosuppressants (IMs), almost all of which are used off-label in the UK. These patients must be closely monitored due to the adverse effect profile of these broad-spectrum therapies. The objective of this study is to quantify the healthcare burden associated with clinical interactions and monitoring of children with moderate-to-severe AD receiving IM therapies.